Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - ams, Wienerberger, Marinomed, Pierer Mobility (24/02/2021)

28.02.2021

ams: ams, Austrian based worldwide supplier of high-performance sensor solutions, and computer vision-based imaging software developer ArcSoft today demonstrated a working system for 3D direct Time-of-Flight (dToF) sensing, offering a complete solution for 3D sensing for use in mobile devices for Android™. Frison Xu, Senior Vice-President and CMO of ArcSoft, said: “The implementation of 3D dToF in mobile devices promises to spark the next wave of killer consumer applications, from photography enhancement to AR interactions, for example in interior styling and photorealistic reconstruction. That is why ArcSoft is excited and honored to work with ams. We will combine ams’ world-leading dToF system with AR and computer vision core engines from ArcSoft to develop a superior imaging and AR experience for consumers. This adds significant value to manufacturers when developing new and exciting mobile apps, due to better lowlight bokeh, fast and accurate auto focus, wide-range, and vivid 3D scene modeling." Lukas Steinmann, Senior Vice-President of the Business Line Sensing, Modules and Solutions at ams, adds: “We see strong potential for broader market adoption of 3D dToF technology for world-facing AR use cases and photo enhancement in high-end Android mobiles from 2022. ams is honored to work with ArcSoft to stake out a leadership position in this market. By combining two complementary, best-in-class technology stacks, together we will enable an optimized AR user experience on high-end mobile platforms.”
AMS: weekly performance: -2.96%

Pierer Mobility: For the financial year 2021, sales between Euro 1,800 – 1,900 mn, an EBIT-margin between 8 – 9 % and an EBITDA-margin exceeding 15 % are expected. Pierer Mobility expects that the demand in the motorized two-wheeler sector remains high in the business year 2021, with a further increase in sales and operating profit compared to the business year 2020. The operating margin in the motorcycle sector is expected to return to pre-crisis levels. Growth is expected to be driven primarily by continued high demand in North America, Australia and China, as well as by the anticipated market recovery in Europe.
Pierer Mobility AG: weekly performance: -1.45%

Marinomed: Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today positive results from its clinical study on the antiviral efficacy of Carragelose-containing lozenges (10 mg iota-carrageenan) in 31 healthy subjects. Results show that lozenges provide an additional formulation complementary to Carragelose-based nasal sprays. Both products are available in pharmacies through Marinomed’s worldwide distributor network. The clinical study evaluated the inhibition of common human respiratory viruses, namely human Rhinoviruses (HRV) 1a and 8, Coronavirus OC43, Influenza A nH1N1 2009, and Coxsackie virus A10. Additionally, the efficacy against SARS-CoV-2 and human Parainfluenza Virus Type 3 was tested. “We are very encouraged by these positive clinical results. After consumption of Carragelose-containing lozenges, saliva was effective against seven different respiratory virus strains, including SARS-CoV-2,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “Recently, positive results from an independent clinical trial were published showing that an iota-carrageenan nasal spray prevented 80 percent of COVID-19 cases among hospital staff. Together with our data on the antiviral efficacy of lozenges, this supports the prophylactic and therapeutic effectiveness of Carragelose products. Using them may help to overcome the ongoing pandemic and represents an additional option for COVID-19 prevention alongside vaccines.”
Marinomed Biotech: weekly performance: -12.86%

Wienerberger: Despite the Covid-19 crisis, brickmaker Wienerberger delivered a highly satisfactory set of results. Group revenues amounted to Euro 3.4 bn (2019: Euro 3.5 bn), almost matching the previous year’s record level. Given its strong performance in the second half of the year, the Group generated EBITDA of Euro 566 mn, substantially surpassing even the previously increased guidance of Euro 545 mn (2019: Euro 594 mn). Net result was affected by non-cash impairments in Q1 2020 and came to Euro 89 mn (2019: Euro 249 mn). In view of recent capital returns and refinancing activity, the Managing Board will propose to the Annual General Meeting that a dividend of Euro 0.60 per share, unchanged from the previous year, be paid out for the 2020 business year. The company said that it is evaluating numerous attractive growth projects offering promising potential for earnings enhancement and compelling returns on invested capital. CEO Heimo Scheuch: "Our target for the business year 2021 is to increase EBITDA LFL to Euro 600 to 620 mn, thus returning to the pre-crisis level, regardless of the Covid-19 related challenges that we continue to face. We will meet this target on the basis of our own strength, without accounting for earnings effects from disposals or acquisitions, such as the acquisition of Meridian Brick, which is still in the approval process."
Wienerberger: weekly performance: -1.98%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/02/2021)


Partners









latest 21st Austria

21st Austria weekly - ams, Wienerberger, Marinomed, Pierer Mobility (24/02/2021)


28.02.2021


ams: ams, Austrian based worldwide supplier of high-performance sensor solutions, and computer vision-based imaging software developer ArcSoft today demonstrated a working system for 3D direct Time-of-Flight (dToF) sensing, offering a complete solution for 3D sensing for use in mobile devices for Android™. Frison Xu, Senior Vice-President and CMO of ArcSoft, said: “The implementation of 3D dToF in mobile devices promises to spark the next wave of killer consumer applications, from photography enhancement to AR interactions, for example in interior styling and photorealistic reconstruction. That is why ArcSoft is excited and honored to work with ams. We will combine ams’ world-leading dToF system with AR and computer vision core engines from ArcSoft to develop a superior imaging and AR experience for consumers. This adds significant value to manufacturers when developing new and exciting mobile apps, due to better lowlight bokeh, fast and accurate auto focus, wide-range, and vivid 3D scene modeling." Lukas Steinmann, Senior Vice-President of the Business Line Sensing, Modules and Solutions at ams, adds: “We see strong potential for broader market adoption of 3D dToF technology for world-facing AR use cases and photo enhancement in high-end Android mobiles from 2022. ams is honored to work with ArcSoft to stake out a leadership position in this market. By combining two complementary, best-in-class technology stacks, together we will enable an optimized AR user experience on high-end mobile platforms.”
AMS: weekly performance: -2.96%

Pierer Mobility: For the financial year 2021, sales between Euro 1,800 – 1,900 mn, an EBIT-margin between 8 – 9 % and an EBITDA-margin exceeding 15 % are expected. Pierer Mobility expects that the demand in the motorized two-wheeler sector remains high in the business year 2021, with a further increase in sales and operating profit compared to the business year 2020. The operating margin in the motorcycle sector is expected to return to pre-crisis levels. Growth is expected to be driven primarily by continued high demand in North America, Australia and China, as well as by the anticipated market recovery in Europe.
Pierer Mobility AG: weekly performance: -1.45%

Marinomed: Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today positive results from its clinical study on the antiviral efficacy of Carragelose-containing lozenges (10 mg iota-carrageenan) in 31 healthy subjects. Results show that lozenges provide an additional formulation complementary to Carragelose-based nasal sprays. Both products are available in pharmacies through Marinomed’s worldwide distributor network. The clinical study evaluated the inhibition of common human respiratory viruses, namely human Rhinoviruses (HRV) 1a and 8, Coronavirus OC43, Influenza A nH1N1 2009, and Coxsackie virus A10. Additionally, the efficacy against SARS-CoV-2 and human Parainfluenza Virus Type 3 was tested. “We are very encouraged by these positive clinical results. After consumption of Carragelose-containing lozenges, saliva was effective against seven different respiratory virus strains, including SARS-CoV-2,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “Recently, positive results from an independent clinical trial were published showing that an iota-carrageenan nasal spray prevented 80 percent of COVID-19 cases among hospital staff. Together with our data on the antiviral efficacy of lozenges, this supports the prophylactic and therapeutic effectiveness of Carragelose products. Using them may help to overcome the ongoing pandemic and represents an additional option for COVID-19 prevention alongside vaccines.”
Marinomed Biotech: weekly performance: -12.86%

Wienerberger: Despite the Covid-19 crisis, brickmaker Wienerberger delivered a highly satisfactory set of results. Group revenues amounted to Euro 3.4 bn (2019: Euro 3.5 bn), almost matching the previous year’s record level. Given its strong performance in the second half of the year, the Group generated EBITDA of Euro 566 mn, substantially surpassing even the previously increased guidance of Euro 545 mn (2019: Euro 594 mn). Net result was affected by non-cash impairments in Q1 2020 and came to Euro 89 mn (2019: Euro 249 mn). In view of recent capital returns and refinancing activity, the Managing Board will propose to the Annual General Meeting that a dividend of Euro 0.60 per share, unchanged from the previous year, be paid out for the 2020 business year. The company said that it is evaluating numerous attractive growth projects offering promising potential for earnings enhancement and compelling returns on invested capital. CEO Heimo Scheuch: "Our target for the business year 2021 is to increase EBITDA LFL to Euro 600 to 620 mn, thus returning to the pre-crisis level, regardless of the Covid-19 related challenges that we continue to face. We will meet this target on the basis of our own strength, without accounting for earnings effects from disposals or acquisitions, such as the acquisition of Meridian Brick, which is still in the approval process."
Wienerberger: weekly performance: -1.98%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/02/2021)




 

Bildnachweis

Aktien auf dem Radar:Telekom Austria, Zumtobel, Rosenbauer, Marinomed Biotech, FACC, EVN, voestalpine, Verbund, RBI, Polytec Group, Rosgix, DO&CO, Semperit, Palfinger, Amag, SW Umwelttechnik, Oberbank AG Stamm, CA Immo, Kapsch TrafficCom, Mayr-Melnhof, SBO, Wienerberger, Warimpex.


Random Partner

Captrace
Captrace ist ein führender Anbieter von Informationssystemen im Bereich Investor Relations. Mit seinem System C◆Tace ermöglicht das Unternehmen dem Emittent größtmögliche Transparenz über seine Investorenstruktur zu erhalten. Durch den Service der Aktionärsidentifikation können Emittenten die Daten ihrer Investoren einfach und zuverlässig über das System C◆Trace von den Banken/Intermediären abfragen.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten